Literature DB >> 10410982

Detection and quantification of complexed and free soluble human vascular endothelial growth factor receptor-1 (sVEGFR-1) by ELISA.

C Hornig1, T Behn, W Bartsch, A Yayon, H A Weich.   

Abstract

Vascular endothelial growth factor (VEGF) is an important factor for endothelial cell proliferation and a key regulator of blood vessel development in embryos and angiogenesis in adult tissues. Its biological activity is mediated by two receptor tyrosine kinases, VEGFR-1 (Flt-1) and VEGFR-2 (KDR). In contrast to VEGFR-2, a naturally occurring soluble form of the VEGFR-1 (sVEGFR-1) is produced by endothelial cells by differential splicing of the flt-1 gene, and it is a secreted gene product. In order to develop a specific enzyme-linked immunosorbent assay (ELISA) for the measurement of sVEGFR-1, we established five anti-human receptor antibodies and characterized them in detail. These antibodies recognize different epitopes located within the seven Ig-like domains of the extracellular receptor protein but have no neutralizing activity in ligand binding assays. Together with a polyclonal antiserum, a specific human sVEGFR-1 ELISA was developed using the mAb #190.11. The ELISA can detect human sVEGFR-1 with a minimum detection limit of 1 ng/ml. The ELISA does not show any cross-reactivity with other related soluble receptors. Using this assay, human sVEGFR-1 was measured in the supernatant of different VEGFR-1 expressing cell types. No sVEGFR-1 protein was detectable after heparin Sepharose treatment or size-exclusion filtration (< 30 kDa). The ELISA assay for sVEGFR-1 was also used to measure the amount of the soluble receptor in amniotic fluid samples of patients undergoing amniocentesis during the course of normal pregnancies. The concentration of the samples was in the range of 5-35 ng/ml. This ELISA could be useful powerful tool for investigations concerning the physiological function of the soluble receptor under normal and pathophysiological conditions.Furthermore, it may facilitate studies of the mechanisms of receptor production.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10410982     DOI: 10.1016/s0022-1759(99)00065-4

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  5 in total

1.  Vascular endothelial growth factor ligands and receptors that regulate human cytotrophoblast survival are dysregulated in severe preeclampsia and hemolysis, elevated liver enzymes, and low platelets syndrome.

Authors:  Yan Zhou; Michael McMaster; Kirstin Woo; Mary Janatpour; Jean Perry; Terhi Karpanen; Kari Alitalo; Caroline Damsky; Susan J Fisher
Journal:  Am J Pathol       Date:  2002-04       Impact factor: 4.307

2.  Soluble and membranous vascular endothelial growth factor receptor-2 in pregnancies complicated by pre-eclampsia.

Authors:  Richa Tripathi; Gayatri Rath; Ranju Ralhan; Sunita Saxena; Sudha Salhan
Journal:  Yonsei Med J       Date:  2009-10-21       Impact factor: 2.759

3.  The soluble VEGF receptor 1 and 2 expression in cerebral spinal fluid as an indicator for leukemia central nervous system metastasis.

Authors:  Yue-Ting Tang; Fang Jiang; Li Guo; Meng-Ya Si; Xiao-Yang Jiao
Journal:  J Neurooncol       Date:  2013-02-12       Impact factor: 4.130

4.  Association between intratumoral free and total VEGF, soluble VEGFR-1, VEGFR-2 and prognosis in breast cancer.

Authors:  H Bando; H A Weich; M Brokelmann; S Horiguchi; N Funata; T Ogawa; M Toi
Journal:  Br J Cancer       Date:  2005-02-14       Impact factor: 7.640

5.  Vascular endothelial growth factor and its soluble receptors VEGFR-1 and VEGFR-2 in the serum of patients with systemic lupus erythematosus.

Authors:  Ewa Robak; Anna Sysa-Jedrzejewska; Tadeusz Robak
Journal:  Mediators Inflamm       Date:  2003-10       Impact factor: 4.711

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.